TY - JOUR
T1 - Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6–48 months with Duchenne muscular dystrophy amenable to exon 51 skipping
AU - Mercuri, Eugenio Maria
AU - Seferian, A. M.
AU - Servais, L.
AU - Deconinck, N.
AU - Stevenson, H.
AU - Ni, X.
AU - Zhang, W.
AU - East, L.
AU - Yonren, S.
AU - Muntoni, F.
AU - Deconinck, Nicolas
AU - Van Coster, Rudy
AU - Vanlander, Arnaud
AU - Seferian, Andreea
AU - De Lucia, Silvana
AU - De Lucia, Sara Sofia
AU - Gidaro, Teresa
AU - Brande, Laura Vanden
AU - Servais, Laurent
AU - Kirschner, Janbernd
AU - Borell, Sabine
AU - Mercuri, Eugenio
AU - Mercuri, Eugenio Maria
AU - Brogna, Claudia
AU - Pane, Marika
AU - Fanelli, Lavinia
AU - Norcia, Giulia
AU - Muntoni, Francesco
AU - Brusa, Chiara
AU - Chesshyre, Mary
AU - Maresh, Kate
AU - Pitchforth, Jaqueline
AU - Schottlaender, Lucia
AU - Scoto, Mariacristina
AU - Silwal, Arpana
AU - Trucco, Fedrica
PY - 2023
Y1 - 2023
N2 - Eteplirsen is FDA-approved for the treatment of Duchenne muscular dystrophy (DMD) in exon 51 skip-amenable patients. Previous studies in boys > 4 years of age indicate eteplirsen is well tolerated and attenuates pulmonary and ambulatory decline compared with matched natural history cohorts. Here the safety, tolerability and pharmacokinetics of eteplirsen in boys aged 6–48 months is evaluated. In this open-label, multicenter, dose-escalation study (NCT03218995), boys with a confirmed mutation of the DMD gene amenable to exon 51 skipping (Cohort 1: aged 24–48 months, n = 9; Cohort 2: aged 6 to < 24 months, n = 6) received ascending doses (2, 4, 10, 20, 30 mg/kg) of once-weekly eteplirsen intravenously over 10 weeks, continuing at 30 mg/kg up to 96 weeks. Endpoints included safety (primary) and pharmacokinetics (secondary). All 15 participants completed the study. Eteplirsen was well tolerated with no treatment-related discontinuations, deaths or evidence of kidney toxicity. Most treatment-emergent adverse events were mild; most common were pyrexia, cough, nasopharyngitis, vomiting, and diarrhea. Eteplirsen pharmacokinetics were consistent between both cohorts and with previous clinical experience in boys with DMD > 4 years of age. These data support the safety and tolerability of eteplirsen at the approved 30-mg/kg dose in boys as young as 6 months old.
AB - Eteplirsen is FDA-approved for the treatment of Duchenne muscular dystrophy (DMD) in exon 51 skip-amenable patients. Previous studies in boys > 4 years of age indicate eteplirsen is well tolerated and attenuates pulmonary and ambulatory decline compared with matched natural history cohorts. Here the safety, tolerability and pharmacokinetics of eteplirsen in boys aged 6–48 months is evaluated. In this open-label, multicenter, dose-escalation study (NCT03218995), boys with a confirmed mutation of the DMD gene amenable to exon 51 skipping (Cohort 1: aged 24–48 months, n = 9; Cohort 2: aged 6 to < 24 months, n = 6) received ascending doses (2, 4, 10, 20, 30 mg/kg) of once-weekly eteplirsen intravenously over 10 weeks, continuing at 30 mg/kg up to 96 weeks. Endpoints included safety (primary) and pharmacokinetics (secondary). All 15 participants completed the study. Eteplirsen was well tolerated with no treatment-related discontinuations, deaths or evidence of kidney toxicity. Most treatment-emergent adverse events were mild; most common were pyrexia, cough, nasopharyngitis, vomiting, and diarrhea. Eteplirsen pharmacokinetics were consistent between both cohorts and with previous clinical experience in boys with DMD > 4 years of age. These data support the safety and tolerability of eteplirsen at the approved 30-mg/kg dose in boys as young as 6 months old.
KW - Clinical trial
KW - Safety
KW - Eteplirsen
KW - Duchenne muscular dystrophy
KW - Clinical trial
KW - Safety
KW - Eteplirsen
KW - Duchenne muscular dystrophy
UR - http://hdl.handle.net/10807/260338
U2 - 10.1016/j.nmd.2023.03.008
DO - 10.1016/j.nmd.2023.03.008
M3 - Article
SN - 0960-8966
VL - 33
SP - 476
EP - 483
JO - Neuromuscular Disorders
JF - Neuromuscular Disorders
ER -